Pharmacokinetics of bambuterol in subjects homozygous for the atypical gene for plasma cholinesterase

British Journal of Clinical Pharmacology

Volumn 45, Issue 5, 1998, Pages 479-484

  Bang, Ulla ^a   Nyberg, Lars ^b   Rosenborg, Johan ^b   Viby Mogensen, Jørgen ^c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Astra Draco AB ^*  (Sweden)

^c Rigshospitalet   (Denmark)

Author keywords

Atypical plasma cholinesterase; Bambuterol; Pharmacokinetics; Terbutaline

Indexed keywords

BAMBUTEROL; CHOLINESTERASE; TERBUTALINE;

AEROBIC METABOLISM; ARTICLE; CAUCASIAN; CHOLINESTERASE BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG URINE LEVEL; ENZYME DEFICIENCY; FEMALE; HEADACHE; HEART PALPITATION; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; MALE; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; RESTLESSNESS; TREMOR;

ADULT; AREA UNDER CURVE; BRONCHODILATOR AGENTS; CHOLINESTERASES; DEBRISOQUIN; FEMALE; GENOTYPE; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PRODRUGS; SYMPATHOLYTICS; TERBUTALINE;

EID: 0031970909     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00697.x     Document Type: Article

References (19)

1. Svensson, L-Å, Tunek, A. The design and bioactivation of presystemically stable prodrugs. Drug Metab Rev 1988; 19: 165-194.
2. Whittaker, M. Plasma cholinesterase variants and the anaesthetist. Anaesthesia 1980; 35: 174-197.
3. Viby-Mogensen, J. Cholinesterase and succinylcholine. Dan Med Bull 1983; 30: 129-150.
4. Bang, U, Viby-Mogensen, J, Wirén, J-E, Theil Skovgaard, L. The effect of bambuterol (carbamylated terbutaline) on plasma cholinesterase activity and suxamethonium-induced neuromuscular blockade in genotypically normal patients. Acta Anaesthesiol Scand 1990; 34: 596-599.
5. Bang, U, Viby-Mogensen, J, Wirén, J-E. The effect of bambuterol on plasma cholinesterase activity and suxamethonium-induced neuromuscular blockade in subjects heterozygous for abnormal plasma cholinesterase. Acta Anaesthesiol Scand 1990; 34: 600-604.
6. Østergaard, D, Kristensen, RW, Bang, U, Pedersen, NA, Viby Mogensen, J. Influence of bambuterol on the pharmacokinetics and pharmacodynamics of mivacurium. Anesthesiology 1995; 83: A899.
7. a. Biochem Pharmacol 1991; 41: 345-348.
8. Nyberg, L, Rosenborg, J, Weibull, E, Jönsson, S, Kennedy, B-M, Nilsson, M. Pharmacokinetics of bambuterol in healthy subjects. Br J Clin Pharmacol 1998; 45: 471-478.
9. Jensen, FS, Skovgaard, LT, Viby-Mogensen, J. Identification of human plasma cholinesterase variants in 6688 individuals using biochemical analysis. Acta Anaesthesiol Scand 1995; 39: 157-162.
10. Kalow, W, Lindsay, HA. A comparison of optical and manometric methods for the assay of human serum cholinesterase. Can J Biochem Physiol 1955; 33: 568-574.
11. Steiner, E, Iselius, L, Alván, G, Lindsten, J, Sjöqvist, F. A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquine. Clin Pharmacol Ther 1985; 38: 394-401.
12. Lindberg, C, Jönsson, S, Paulsson, J. Determination of bambuterol, a prodrug of terbutaline in plasma and urine by gas chromatography/mass spectrometry. Biomed Environ Mass Spectrom 1990; 19: 218-224.
13. Kennedy, B-M, Blomgren, A, Edholm, L-E, Roos, C. Quantitative determination of terbutaline in human plasma after administration of bambuterol using coupled columns and electrochemical detection. Chromatographia 1987; 24: 895-899.
14. Lindberg, C, Roos, C, Tunek, A, Svensson, LÅ. Metabolism of bambuterol in rat liver microsomes: identification of hydroxylated and demethylated products by liquid chromatography mass spectrometry. Drug Metab Disp 1989; 17: 311-322.
15. Islam, SA, Wolf, CR, Lennard, MS, Sternberg, MJE. A three-dimensional molecular template for substrates of human cytochrome P450 involved in debrisoquine 4-hydroxylation. Carcinogenesis 1991; 12: 2211-2219.
16. Strobl, GR, von Kruedener, S, Stöckigt, J, et al. Development of a pharmacophore for inhibition of human liver cytochrome P-450, 2D6: Molecular modeling and inhibition studies. J Med Chem 1993; 36: 1136-1145.
17. Steiner, E, Bertilsson, L, Säwe, J, et al. Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther 1988; 44: 431-435.
18. Brøsen, K, Otton, SV, Gram, LF. Sparteine oxidation polymorphism in Denmark. Acta Pharmacol Toxicol 1985; 57: 357-360.
19. Madsen, H, Kramer-Nielsen, K, Brosen, K. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms - A population study. Br J Clin Pharmacol 1995; 39: 433-439.